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Emergency presentation of cancer and
short-term mortality
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Hospital, Leeds LS9 7TF, UK and 5NHS England, 18th Floor, Portland House, Bressenden Place, Victoria, London SW1E 5RS, UK
Background: The short-term survival following a cancer diagnosis in England is lower than that in comparable countries, with the
difference in excess mortality primarily occurring in the months immediately after diagnosis. We assess the impact of emergency
presentation (EP) on the excess mortality in England over the course of the year following diagnosis.
Methods: All colorectal and cervical cancers presenting in England and all breast, lung, and prostate cancers in the East of
England in 2006–2008 are included. The variation in the likelihood of EP with age, stage, sex, co-morbidity, and income
deprivation is modelled. The excess mortality over 0–1, 1–3, 3–6, and 6–12 months after diagnosis and its dependence on these
case-mix factors and presentation route is then examined.
Results: More advanced stage and older age are predictive of EP, as to a lesser extent are co-morbidity, higher income
deprivation, and female sex. In the first month after diagnosis, we observe case-mix-adjusted excess mortality rate ratios of
7.5 (cervical), 5.9 (colorectal), 11.7 (breast ), 4.0 (lung), and 20.8 (prostate) for EP compared with non-EP.
Conclusion: Individuals who present as an emergency experience high short-term mortality in all cancer types examined
compared with non-EPs. This is partly a case-mix effect but EP remains predictive of short-term mortality even when age, stage,
and co-morbidity are accounted for.
Improving cancer survival is a key challenge identified in
Improving Outcomes: A Strategy for Cancer (Department of
Health, 2011). Cancer survival estimates in England currently fall
below those in many European countries across most cancer types
(Berrino et al, 2007; Richards, 2007; Verdecchia et al, 2007). It has
been estimated that if cancer survival in England was made
comparable to the European average then 5000 or more deaths
within 5 years of diagnosis could be avoided annually (Abdel-
Rahman et al, 2009; Richards, 2009).
If analyses are restricted to include only those who survive at
least 1 year from diagnosis, then the difference in 5-year survival
between England and European countries is, in general, smaller
(Thomson and Forman, 2009). Examination of excess mortality in
the first year after diagnosis shows that, in particular, it is
substantially greater in England than both Norway and Sweden in
the first months after diagnosis for breast, colorectal, and lung
cancer (Engholm et al, 2007; Holmberg et al, 2010; Møller et al,
2010). This would indicate that the long-term survival differences
observed between England and other countries are at least partly a
result of a higher number of deaths shortly after diagnosis.
Understanding the mechanism that causes these excess deaths
could assist in reducing their number, potentially improving long-
term outcomes in England.
Recent work shows that the route a patient follows on the way to
the diagnosis of their cancer is strongly predictive of 1-year
survival (Elliss-Brookes et al, 2012), with those who present as an
emergency faring poorly in the first year after diagnosis. In 11 of
15 cancer types examined, emergency presentations (EP) have a
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1-year relative survival, which is 425% lower than those
presenting via other routes. Elliss-Brookes et al (2012) shows EPs
to be more likely in older patients. One can hypothesise that the
lower survival is because of confounding by age and other cofactors
generally detrimental to overall health.
Some literature exists on levels of EP internationally,
primarily for colorectal cancer. Levels of colorectal EP reported
vary: Greece 12%; Australia 16%; Sweden 17%; Canada 24%;
Norway 25% (Mitchell et al, 2007; Pavlidis et al, 2008; Wong
et al, 2008; Sjo et al, 2009; Gunnarsson et al, 2011). These
studies tend to be based at single centres, comparatively small
(o2000 patients), and based on data stretching back to the
1990s or 1980s. Case finding in secondary care may also
overstate the levels of EP compared with population-based
studies. Levels of EP in England, at 26% (Elliss-Brookes et al,
2012), appear comparable to or higher than internationally, at
least for colorectal cancer. Emergency presentation is an
informative measure with regard to death in the first year after
diagnosis, and exploration of how EPs occur may help
illuminate the difference in 1-year survival between England
and comparable countries.
Stage at diagnosis is known to be highly predictive of cancer
mortality and later stage at diagnosis is a possible explanation for
the difference in cancer survival between England and Europe
(Sant et al, 2003; Foot and Harrison, 2011). The completeness of
staging data available varies by cancer type and by geographical
region of registration. Consequently, this study is confined to
cancer types where stage completeness is high enough to be
analytically useful and case numbers are high enough for
meaningful statistical power. For England as a whole these are
colorectal and cervical cancers, and for the East of England (the
former Eastern Cancer Registration and Information Centre,
ECRIC, registration area) these are breast, lung, and prostate
cancers. These cancers have a wide span in the proportion of
observed EPs ranging from 5% for breast cancers to 39% for lung
cancers; this allows the impact of EP across a range of very
different cancer types to be examined.
This study explores the impact of emergency vs non-EP routes
with two keys aims: to assess the sociodemographic and clinical
variables associated with EP; and to test the hypothesis that these
cofactors explain the association between EP and short-term
mortality.
MATERIALS AND METHODS
All newly diagnosed invasive tumours excluding non-melanoma
skin cancer (ICD-10 C00-C97 excluding C44) diagnosed between
2006 and 2008 in residents of England were extracted from the
National Cancer Data Repository (NCDR), with available informa-
tion on stage at diagnosis (National Cancer Intelligence Network,
2011). The NCDR contains all cases of cancer known to the
English cancer registries, with a case ascertainment of 98–99%
(Møller et al, 2011). Dates of death in the NCDR are derived by
record level linkage with ONS mortality records and include all
deaths, not just those in hospital. The NCDR data set was
de-duplicated using European Network of Cancer Registries
criteria (Parkin et al, 1994), removing 7% of cases. The ‘Route to
Diagnosis’ for each case was categorised from routinely available
cancer data using a detailed algorithm explained in Elliss-Brookes
et al (2012). The eight possible routes derived there were
aggregated here to two categories—EPs and non-EPs. In on 131
754 cases were diagnosed with the cancer types and within the
geographical regions of interest. Of these, 2161 cases (1.6%) were
excluded on the basis that they were a death certificate only
registration; were aged over 99 years at diagnosis; were reported as
stage 0 for breast cancer; or had a misordered date of birth, date of
diagnosis, and date of death.
The completeness of cancer staging within the NCDR varies
strongly with cancer type. For colorectal cancer (ICD-10 codes
C18-C20), 68% of cases in England diagnosed in 2006–2008 had a
valid Dukes stage recorded. For cervical cancer (ICD-10 C53), 74%
of cases in England in the same period had a valid FIGO stage
recorded. Cases contributed to the NCDR by the ECRIC had an
overall completeness of integrated TNM stage group of 93% (breast
cancer: ICD-10 C50), 78% (lung cancer: ICD-10 C33–34), and
95% (prostate cancer: ICD-10 C61).
The Charlson co-morbidity index was created from diagnostic
codes (ignoring cancer codes) recorded in the inpatient Hospital
Episode Statistics (HES) data set for each patient in the period
from 30 months before diagnosis to 3 months before diagnosis.
Diagnostic codes relating to independent secondary cancers were
sourced from the NCDR over the same period. A Charlson index
was derived from these diagnostic codes using a lookup
table (Quan et al, 2005). For purposes of generating a Charlson
index, the HES records available were limited to those persons with
a diagnostic code of cancer recorded at any point in any of their
HES records (i.e., all records before diagnosis are available if at
least one record contains a cancer code).
The income deprivation quintile was derived by linking each
tumour to the Index of Multiple Deprivation 2007 (Communities
and Local Government, 2007) using postcode at the time of
diagnosis. Equal population quintiles were derived from the
income domain score.
Multiple imputation (Nur et al, 2010) was used to generate
missing values for stage and co-morbidity. The ice (Royston, 2005)
and mim (Carlin et al, 2008) programs were used to perform
imputation in Stata 10.1 (StataCorp, 2007). Imputation was
performed on stage and co-morbidity with sex, income deprivation
quintile, type of presentation, cancer registry, a binary variable
indicating observed metastatic spread or not, age, and survival time
included in the imputation model, with no interaction terms. Ten
imputed data sets were created.
Sensitivity analysis of the impact of multiple imputation was
performed by repeating regression analyses without imputation,
with missing cases excluded (a ‘completer analysis’), and by
assuming that missing values of stage and co-morbidity took the
most extreme plausible values.
Factors predictive of EP were explored through binary logistic
regression with the fact of EP as the dependent variable and the
demographic and clinical factors as categorical independent
variables.
Excess mortality was modelled using the strs program (Dickman
et al, 2004) in Stata 10.1. Regression analysis used a generalised
linear model with a Poisson error structure on collapsed data
(Dickman et al, 2004), and persons aged o25 were excluded.
Proportional hazards are not assumed because of different
variation with time of different cofactors, instead a separate
analysis is undertaken for each time period with ordinal
independent variables. This ordinal assumption constrains the
model to a geometrically increasing series of rate ratios with each
increase in one of the independent variables. Sensitivity analyses
were performed as for the first regression model.
RESULTS
Over the 3-year period from 2006 to 2008, 131 754 newly
diagnosed malignant cancers of interest were diagnosed in England
or the ECRIC area. Table 1 shows the number of tumours included
and excluded and the proportion of EPs broken down by age,
co-morbidity, sex, income deprivation, and the stage at diagnosis
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for colorectal and cervical tumours at a national level and for
breast, lung, and prostate tumours in the ECRIC registration area.
Overall, the fraction of EPs increases with age, although for
colorectal cancer in particular there is a non-monotonic relation-
ship with a higher fraction presenting as an emergency in those
aged 0–24 than those aged 25–64 (albeit with a small cohort size in
the younger age group). The proportion of EPs increased with
increasing co-morbidity, was higher in women compared with
men, and increased with increasing income deprivation.
Across all tumour types, the proportion of EP increased with
increasing stage. In early-stage breast, prostate, and cervical cancer,
this proportion was o5%, whereas Dukes A colorectal cancers
had 11% EP and TNM stage group 1 lung cancers had 25% EP.
For cases without a recorded stage, the proportion of EP was
broadly similar to those in cases with a later stage at presentation.
Figure 1 shows excess mortality in five cancer types in the year
following diagnosis, for EP and non-EP separately and combined,
in persons diagnosed between 2006 and 2008. The excess mortality
is substantially higher in EPs, varying between a rate of
162 (prostate cancer); 190 (cervical cancer); 295 (breast cancer);
297 (colorectal cancer); and 635 (lung cancer) deaths per
100 person-years exposure time in the month immediately
following diagnosis. In non-EPs, these rates became 5 (prostate
and breast cancer); 10 (cervical cancer); 38 (colorectal cancer), and
140 (lung cancer) deaths per 100 person-years. Excess mortality
remains elevated for persons presenting by EP in later periods
Table 1. Numbers of cancers and proportions diagnosed via EP for persons resident in England (cervical and colorectal) and the ECRIC registration area
(breast, lung, and prostate) diagnosed in 2006–2008
England ECRIC registration area
Cervical Colorectal Breast Lung Prostate
Characteristic n %EPs n %EPs n %EPs n %EPs n %EPs
Number
n 6950 12% 89 484 26% 12 354 4% 9601 36% 11 204 7%
Excluded 50 — 1932 — 79 — 71 — 29 —
Age
0–24 151 11% 159 58% 9 0% 3 0% 0 —
25–64 5264 8% 24 283 20% 6797 1% 2370 29% 2553 3%
65–84 1251 22% 54 026 24% 4545 5% 6087 36% 7677 6%
85þ 284 41% 11 016 43% 1003 16% 1141 54% 974 26%
Co-morbidity
Not known 982 5% 5723 26% 1744 4% 1035 31% 3088 4%
0 5569 13% 71 274 24% 9822 4% 6829 36% 6894 7%
1 243 21% 6708 34% 513 7% 979 41% 680 11%
2 103 26% 3777 31% 190 7% 453 41% 364 14%
3þ 53 36% 2002 40% 85 9% 305 43% 178 13%
Sex
Male — — 49515 23% — — 5602 35% 11 204 7%
Female 6950 12% 39 969 29% 12 354 4% 3999 38% — —
Income deprivation
Least deprived 1089 8% 18 349 22% 2962 3% 1579 33% 2725 5%
2 1243 11% 20 087 24% 3334 4% 2170 34% 3081 6%
3 1338 13% 19 398 25% 3058 4% 2583 36% 2933 8%
5 1489 12% 17 459 27% 2229 5% 2251 39% 1859 8%
Most deprived 1791 15% 14 191 31% 771 5% 1018 40% 606 10%
Stage
Not known 1823 19% Not Known 28 449 30% Not Known 922 11% 2154 41% 527 18%
FIGO 1 3324 3% A (Dukes) 8718 8% TNM 1 4754 1% 1115 21% 51 2%
FIGO 2 906 14% B (Dukes) 21 652 22% TNM 2 5113 2% 462 19% 7794 3%
FIGO 3 490 24% C (Dukes) 21 498 26% TNM 3 1013 8% 2491 31% 1270 4%
FIGO 4 407 41% D (Dukes) 9167 36% TNM 4 552 29% 3379 44% 1562 23%
Imputed stage
FIGO 1 4359 4% A (Dukes) 12 651 11% TNM 1 5118 1% 1564 25% 54 3%
FIGO 2 1278 16% B (Dukes) 31 569 23% TNM 2 5554 3% 686 26% 8244 4%
FIGO 3 730 29% C (Dukes) 33 283 29% TNM 3 1130 11% 3969 36% 1343 5%
FIGO 4 584 45% D (Dukes) 11 981 37% TNM 4 552 29% 3382 44% 1562 23%
Abbreviations: ECRIC¼Eastern Cancer Registration and Information Centre; EP¼emergency presentations; TNM¼ tumour node metastasis stage group; FIGO = International Federation of
Gynecology and Obstetrics stage.
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examined and is of comparable magnitude in breast, colorectal,
and prostate cancer. Unadjusted excess mortality rate ratios
between EP and non-EP cases in the first month after diagnosis
are 4.5 (lung cancer), 7.8 (colorectal cancer), 18.5 (cervical cancer),
34.2 (prostate cancer), and 55.1 (breast cancer).
Table 2 shows odds ratios for EP for persons diagnosed between
2006 and 2008. Emergency presentations are more common
for younger ages and older ages; more common in women
(the lung cancer result is statistically significant at a 95% level);
more common in more income-deprived persons; and more
common in later-stage cancers. These effects are broadly consistent
across all cancer types, with odds ratios for increasing age and stage
having the largest magnitudes.
Comparison of odds ratios for EP with and without the use of
stage imputation shows either statistically insignificant differences
or differences that, although statistically significant, do not greatly
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Figure 1. Unadjusted excess mortality rates for emergency (dotted), non-emergency (dashed), and all presentation (solid) routes in the periods
0–1, 1–3, 3–6, and 6–12 months after diagnosis, plotted semilogarithmically at the central point of those periods with 95% confidence intervals.
Figures represent all persons diagnosed with selected cancer types in England (cervical and colorectal cancer) and the ECRIC registration
area (breast, lung, and prostate cancer), 2006–2008. Stage and co-morbidity include imputed values.
Table 2. Odd ratios for emergency presentation and 95% CIs from a multivariate logistic model
England ECRIC area
Cervical Colorectal Breast Lung Prostate
Characteristic OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Sex
Male — 1.0 — 1.0 —
Female — — 1.3 (1.2–1.3) — — 1.1 (1.0–1.2) — —
Stage
FIGO 1 1.0 Dukes A 1.0 TNM 1 1.0 1.0 0.6 (0.1–5.4)
FIGO 2 3.7 (2.8–4.9) Dukes B 2.3 (2.2–2.5) TNM 2 1.1 (0.2–4.6) 1.1 (0.8–1.5) 1.0
FIGO 3 7.4 (5.3–10.3) Dukes C 3.3 (3.1–3.6) TNM 3 3.7 (0.9–16.0) 1.8 (1.5–2.1) 1.3 (1.0–1.8)
FIGO 4 14.7 (11.1–19.6) Dukes D 4.8 (4.5–5.2) TNM 4 13.9 (3.2–59.7) 2.7 (2.4–3.2) 5.9 (5.0–7.0)
Age
0–24 1.5 (0.9–2.7) 5.5 (4.0–7.6) — — —
25–64 1.0 1.0 1.0 1.0 1.0
65–84 1.5 (1.2–1.8) 1.3 (1.2–1.3) 3.5 (2.7–4.6) 1.4 (1.2–1.5) 1.5 (1.2–1.9)
85þ 2.9 (2.1–3.9) 2.8 (2.6–2.9) 11.1 (8.3–14.8) 3.1 (2.7–3.6) 7.0 (5.4–9.2)
Co-morbidity
Charlson 0 1.0 1.0 1.0 1.0 1.0
Charlson 1 1.1 (0.8–1.6) 1.5 (1.4–1.6) 1.3 (0.8–2.0) 1.2 (1.0–1.4) 1.2 (0.9–1.5)
Charlson 2 1.5 (0.9–2.5) 1.4 (1.3–1.5) 1.4 (0.7–2.8) 1.3 (1.1–1.6) 1.8 (1.2–2.7)
Charlson 3þ 1.6 (0.9–3.1) 2.0 (1.8–2.2) 1.3 (0.6–2.8) 1.4 (1.1–1.8) 1.5 (0.9–2.5)
Income deprivation
Least deprived 1.0 1.0 1.0 1.0 1.0
2 1.3 (1.0–1.8) 1.1 (1.0–1.1) 0.9 (0.7–1.3) 1.0 (0.9–1.2) 1.0 (0.8–1.3)
3 1.4 (1.1–1.9) 1.2 (1.1–1.2) 1.0 (0.8–1.4) 1.2 (1.0–1.3) 1.3 (1.0–1.7)
4 1.3 (1.0–1.8) 1.3 (1.2–1.3) 1.2 (0.9–1.6) 1.3 (1.1–1.5) 1.4 (1.1–1.7)
Most Deprived 1.6 (1.2–2.2) 1.6 (1.5–1.7) 1.2 (0.8–1.9) 1.4 (1.2–1.6) 1.7 (1.2–2.4)
Abbreviations: CI¼ confidence interval; ECRIC¼Eastern Cancer Registration and Information Centre; OR¼odds ratio. Persons resident in England (cervical and colorectal) or the ECRIC
registration area (breast, lung, and prostate) diagnosed in 2006–2008. Stage and co-morbidity include imputed values.
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change the magnitude of the odds ratios presented (complete case
analysis is included in Supplementary Information). Pairwise
examination of all interaction terms shows some that are
statistically significant. However, the change in the odds of EP is
small compared with the magnitude of the odds in all but one case.
The exception is for patients aged o25, for which substantial
interactions were found.
Table 3 shows excess mortality rate ratios modelled for
persons diagnosed between 2006 and 2008. There is a broad
consistency across the cancer types examined. The excess
mortality rate ratio for EP (compared with non-EP) and
increasing age is highest for periods immediately after diagnosis;
for increasing stage, the excess mortality rate ratio is highest
for later periods. The excess mortality rate ratios for increasing
co-morbidity and increasing income deprivation are compara-
tively small in magnitude compared with those of stage and age,
and those for sex (for lung and colorectal cancer) are close to
unity.
The dependence of excess mortality rate ratios on EP for the
month after diagnosis are highest for prostate and breast cancer,
and lower for lung and colorectal cancer. Prostate cancer shows the
highest dependence on age and breast cancer on stage in this same
month.
Regression coefficients recalculated after excluding stage 1–3
prostate cancer, stage 1–2 breast cancer, and stage 1 cervical
cancer were not statistically significantly different from those
presented in Table 3, although the rate ratio of the excess
mortality for prostate cancer in the first month after diagnosis
was reduced to 11.8 (95% confidence interval: 5.2–26.9). Pairwise
examination of all interaction terms shows some that are
statistically significant. However, the change in the excess
mortality rate ratio because of EP is small compared with its
magnitude in all cases. The model for cervical cancer was mildly
improved by including an interaction term between stage and age.
Comparison of excess mortality rate ratios with and without the
use of stage imputation shows either statistically insignificant
differences or differences that, although statistically significant,
do not greatly change the magnitude of the rate ratios
presented (complete case analysis is included in Supplementary
Information).
Table 3. Excess mortality rate ratios and 95% confidence intervals at 0–1, 1–3, 3–6, and 6–12 months after diagnosis from a multivariate model
England ECRIC registration area
Cervical Colorectal Breast Lung Prostate
Period/characteristic EMRR 95% CI EMRR 95% CI EMRR 95% CI EMRR 95% CI EMRR 95% CI
0–1 month
Presentation route 7.5 (4.9–11.1) 5.9 (5.6–6.2) 11.7 (7.8–17.4) 4.0 (3.7–4.4) 20.8 (11.7–36.3)
Age 2.0 (1.6–2.5) 2.1 (2.0–2.2) 1.9 (1.5–2.4) 1.6 (1.4–1.7) 3.0 (2.1–4.2)
Co-morbidity 1.3 (1.0–1.6) 1.2 (1.1–1.2) 1.4 (1.0–1.8) 1.1 (1.0–1.1) 1.4 (1.1–1.8)
Sex — — 1.1 (1.0–1.1) — — 0.9 (0.8–0.9) — —
Income deprivation 0.9 (0.8–1.0) 1.1 (1.0–1.1) 1.0 (0.9–1.2) 1.0 (1.0–1.1) 1.1 (0.9–1.3)
Stage 1.7 (1.4–2.1) 1.5 (1.4–1.5) 3.0 (2.4–3.7) 1.2 (1.2–1.3) 1.0 (0.8–1.3)
1–3 months
Presentation route 2.3 (1.7–3.1) 2.4 (2.3–2.6) 3.2 (1.9–5.3) 2.4 (2.2–2.6) 5.2 (3.4–8.0)
Age 2.1 (1.7–2.6) 1.9 (1.8–2.0) 2.3 (1.6–3.2) 1.4 (1.3–1.5) 2.7 (1.9–3.9)
Co-morbidity 1.2 (1.0–1.4) 1.2 (1.1–1.2) 1.1 (0.5–1.9) 1.1 (1.0–1.2) 1.3 (1.0–1.6)
Sex — — 1.0 (1.0–1.1) — — 1.0 (0.9–1.1) — —
Income deprivation 1.1 (1.0–1.2) 1.1 (1.0–1.1) 1.0 (0.8–1.2) 1.0 (1.0–1.0) 1.1 (0.9–1.3)
Stage 2.2 (1.8–2.5) 2.2 (2.1–2.2) 5.2 (3.6–7.5) 1.6 (1.5–1.7) 2.9 (2.2–4.0)
3–6 months
Presentation route 2.3 (1.7–3.1) 1.8 (1.7–1.9) 2.3 (1.3–4.0) 1.7 (1.5–2.0) 6.6 (4.0–10.8)
Age 2.2 (1.8–2.7) 1.8 (1.7–1.9) 2.0 (1.4–2.9) 1.4 (1.3–1.5) 1.9 (1.2–2.8)
Co-morbidity 1.2 (0.9–1.5) 1.3 (1.2–1.3) 1.8 (1.3–2.4) 1.1 (1.0–1.2) 1.9 (1.6–2.3)
Sex — — 1.1 (1.0–1.2) — — 0.9 (0.8–1.0) — —
Income deprivation 1.0 (0.9–1.1) 1.1 (1.0–1.1) 1.3 (1.0–1.5) 1.0 (1.0–1.1) 0.9 (0.8–1.1)
Stage 2.3 (1.9–2.7) 2.6 (2.4–2.7) 5.1 (3.7–7.0) 1.8 (1.6–1.9) 2.2 (1.7–3.0)
6–12 months
Presentation route 2.7 (2.2–3.4) 1.7 (1.6–1.8) 2.1 (1.4–3.3) 1.3 (1.2–1.5) 2.5 (1.6–4.0)
Age 1.6 (1.3–1.9) 1.5 (1.4–1.6) 1.9 (1.5–2.4) 1.3 (1.2–1.5) 1.0 (0.7–1.5)
Co-morbidity 1.2 (1.0–1.4) 1.3 (1.2–1.3) 1.7 (1.3–2.1) 1.0 (0.9–1.1) 1.4 (1.1–1.8)
Sex — — 1.1 (1.0–1.2) — — 0.9 (0.9–1.0) — —
Income deprivation 1.1 (1.0–1.2) 1.0 (1.0–1.1) 1.0 (0.9–1.2) 1.0 (1.0–1.0) 1.0 (0.9–1.2)
Stage 2.2 (1.9–2.4) 3.1 (2.9–3.2) 4.1 (3.4–4.9) 1.7 (1.6–1.9) 7.5 (3.3–17.0)
Abbreviations: CI¼ confidence interval; ECRIC¼Eastern Cancer Registration and Information Centre; EMRR¼excess mortality rate ratio. Rate ratios show the increase in excess mortality in
the period per step increase in presentation (non-emergency or emergency), age (25–64, 65–84, or 85þ ), co-morbidity (Charlson 0, 1, 2, 3þ ), sex (male or female), income deprivation (quintiles
from least to most income deprivation), or stage (increasing FIGO, Dukes, or TNM-integrated stage on a four-point scale). The model included persons resident in England (cervical and
colorectal cancer) or the ECRIC registration area (breast, lung, and prostate cancer) diagnosed in 2006–2008. Stage and co-morbidity include imputed values.
Emergency Presentation BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.569 2031
DISCUSSION
This study presents a two-step analysis of EP of cancer, as
categorised from routinely available health service data. We show
EP to be highly predictive of cancer mortality in the year
following diagnosis, and especially in the month following
diagnosis. That EPs were more common with older age and
more advanced stage was expected: we demonstrate a case-mix
effect in the frequency of EP because of stage and age at
presentation across all cancer types examined with a lesser effect
owing to co-morbidity, deprivation, and female sex (where
relevant). Excess mortality was strongly associated with EP,
independently of case-mix factors, disproving the hypothesis that
it is because of these factors alone.
Strengths and weaknesses. An advantage of using routine data is
the population basis of the patient cohort, thereby representing all
cancers diagnosed (and without demanding additional intrusive
patient contact). The ECRIC registration area has a population of
around 5.5 million (similar to Scotland, Denmark, and Norway)
and has overall cancer survival comparable to that of England
(Quaresma et al, 2012). The fraction of EPs in the ECRIC area for
breast, lung, and prostate cancer is similar to that for England as a
whole (Elliss-Brookes et al, 2012). Cancer staging within the
ECRIC registration area is to a consistent standard and of high
completeness. Together, these observations support an argument
that the results for the ECRIC area, especially once adjusted for
case-mix, are robust and applicable to the broader English
population.
The independent variables selected (age, sex, and income
deprivation) cover major demographic causes for variation in
mortality, as well as clinical causes attributed to the cancer itself
(stage) and pre-existing health (co-morbidity). Performance status
was not available as an independent variable, but one could
anticipate that age and co-morbidity may act as a partial proxy
factors for it.
Age, sex, and income deprivation are recorded with high
completeness. One can criticise the assignment of the income
deprivation score on the grounds of the ecological fallacy, as the
lower super output areas used to assign a quintile have an average
population of around 1600 persons. This may have the effect
of reducing the observed impact of income deprivation compared
to the actual impact. Stage and co-morbidity data are to some
extent incomplete, as shown in Table 1. Reasons for missing stage
data might be treatment outside NHS secondary care, death before
staging was complete, or a lack of data transfer to cancer registries
of key data (e.g. nodal status) needed to compute a stage. Co-
morbidity data are missing because of the absence of an available
HES record in the period before diagnosis. The variables in the
imputation model can be expected to be sensitive to these different
mechanisms and therefore make the missing at random assump-
tion plausible.
There are several assumptions built into the assignment of a co-
morbidity score. As scores are drawn from previous inpatient
admissions they will not count anyone with a significant condition
that is treated exclusively in outpatient or primary care, and they
also only count those with an inpatient admission in the designated
period. It is therefore plausible then that the influence of co-
morbidity is under-represented in this study to a degree, although
the higher the degree of decompensation from co-morbidity (in the
years immediately before diagnosis) the more likely that this fact
will be captured.
Overall, as far as can be determined, the results are
methodologically robust. Sensitivity analyses show that the
relationships between the likelihood of EP and the independent
variables examined, and between EP and short-term mortality are
not greatly affected by the imputation performed. The one
substantial interaction term found in the model for the likelihood
of EP – for persons aged o25 – is itself a plausible exception
because of the very different referral pathways for these patients.
Modelling the excess mortality rate ratios using ordinal indepen-
dent variables gives good agreement with a similar, but categorical,
model for colorectal cancer (Downing et al, 2013).
Variation in mortality. The overall (unadjusted) excess mortality
observed in Figure 1 is consistent with other studies in magnitude
and in variation over time following diagnosis for breast, colorectal,
and lung cancer (Engholm et al, 2007; Holmberg et al, 2010; Møller
et al, 2010). All show higher excess mortality in the first months
after diagnosis, which quickly falls off towards the end of the first
year after diagnosis. However, the variation in excess mortality
between EPs and non-EPs in the period immediately after
diagnosis (0–1 month for breast cancer and 0–3 months for lung
and colorectal cancer) is greater than that between the youngest
and oldest age groups in prior studies. Patients presenting as
emergencies with breast, cervical, colorectal, or prostate cancer
experience higher mortality in the first month after diagnosis than
those presenting with lung cancer as non-emergencies.
The impact of EP on short-term mortality observed here is
consistent with that in other studies. A wide literature exploring
this association exists for colorectal cancer, (e.g. Faiz et al, 2010;
Downing et al, 2013), but few studies exist for other cancer types. It
has been shown that mortality within 30 days of a diagnosis of
breast (and colorectal) cancer is associated with an emergency
admission within 30 days before or after diagnosis (Brewster et al,
2011). Moreover, a case finding study of cancer patients across all
tumour types in Northern Ireland who died in hospital (Blaney
and Gavin, 2011) showed that 79% of deaths followed emergency
admissions (this included admissions with previously known
cancers as well as EP via an emergency inpatient admission).
Multivariate modelling of the excess mortality rate ratio to take
into account selected case-mix factors showed that, as for the
unadjusted case, the impact of EP was most marked in the first
month after the diagnosis (Table 3). We saw a range in adjusted
excess mortality rate ratios between 4.0 (lung) and 20.8 (prostate
cancer). The impact of EP fell with time, although EPs still carried
a higher risk of mortality at later periods, even when other factors
were accounted for. In contrast, the impact of stage on excess
mortality either stayed broadly the same within the different time
intervals (cervical cancer) or increased with the time since
diagnosis (breast, colorectal, lung, and prostate cancer). This
difference in the dependence of excess mortality rate ratios on time
implies that the causes of mortality following EP are more complex
than a simple dependence on tumour stage.
For lung and colorectal cancer, case-mix had a comparatively
small effect on the excess mortality rate ratio for EP compared with
non-EP in the first month after diagnosis. For breast, cervical, and
prostate cancer, the adjusted mortality rate ratio in the first month
after diagnosis is reduced compared with the unadjusted figure, but
still substantial and comparable to or greater in magnitude than the
effect of stage or age. In contrast, the low dependence of the excess
mortality rate ratios on sex and income deprivation suggests that
patient demographics are of more importance in determining the
route of presentation than the subsequent mortality within that
route.
The fraction of excess mortality in the first month because of EP
alone can be estimated: if the multivariate model is adjusted such
that the excess mortality rate ratio for EP is 1.0, while holding other
rate ratios constant, we then predict that the excess mortality in the
first month falls to between 30 and 50% of the observed figure for
all five cancer types. This simple approach overestimates the
impact of EP as it would not account for the deaths which would
then be expected to take place in the additional patient exposure
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time introduced, but it suggests that the contribution of EP to
mortality in the first month following diagnosis is of the order of a
half. A better estimate of the impact of EP requires a better
understanding of their nature.
The nature of EP. Emergency presentation can be viewed as an
extreme expression of the waiting time paradox (Crawford et al,
2002; Tørring et al, 2011) where the outcomes are poor but the
‘waiting time’ is very short. The hypotheses to explain these poor
outcomes that go beyond the influence of the independent
variables already considered are of great interest. These can be
broadly summarised as:
First, residual confounding by independent variables not
considered (such as performance status) or imperfectly defined
(co-morbidity or income deprivation) is a possibility. However, it is
difficult to explain the magnitude of the excess mortality rate ratios
for EP in the first month after diagnosis via this mechanism.
Second, mortality is because of other co-morbidities with a
sudden onset, that is, the cancers are being diagnosed incidentally
as an emergency. However, it was estimated that only 1 in 19 to 1
in 15 of calculated presentation routes are because of incidental
admissions (Elliss-Brookes et al, 2012), only some of which will be
emergencies. The (low) proportion of EP in early-stage breast and
prostate cancer could be explained by this mechanism but
sensitivity analysis, which excludes early-stage tumours from the
analysis shows little impact on the observed dependence of excess
mortality on EP, implying that this is not a major overall influence.
Third, EPs occur preferentially with advanced complications
(Hamilton, 2012), or EP tumours are preferentially faster growing
or otherwise associated with higher mortality (e.g., because of
physical location in an organ). The nature of the tumour, beyond
its stage, plausibly affects both route of presentation and the short-
term outcome. For example, colorectal tumours that cause an
obstruction or perforation of the bowel are likely to be EPs with
poor outcomes. Further confounding is also possible: colorectal
tumours presenting higher in the colon are likely to be more
frequently EPs (because of less specific symptoms) and to have
worse outcomes (because of the comparative inaccessibility).
Fourth, excess mortality is because of presentation at night or on
weekends or to non-specialist centres where clinical services are
less available or less capable. An emergency inpatient admission
(which occurs during the majority of EPs) caused by cancer can
occur for disparate reasons including metabolic emergencies,
cardiovascular emergencies, infectious emergencies, and respira-
tory emergencies (Lewis et al, 2011). They are challenging to
manage with the potential for rapidly deleterious effects (Samphao
et al, 2009; Royal College of Physicians and Royal College of
Radiologists, 2012). In these circumstances, excess mortality could
be due to either the absence of (or delay to) specialist care or due to
iatrogenic causes.
The widespread impact of EP on 1-year cancer survival (Elliss-
Brookes et al, 2012), the lack of sensitivity to case-mix adjustment
in lung and colorectal cancer, and the uniformly high (unadjusted)
excess mortality rates in EPs suggest that a common mechanism,
or mechanisms, may be at work for all cancers. Overall, this study
is consistent with a mixture primarily of the third and fourth
hypotheses.
Improving outcomes. The mortality associated with EP might be
reduced by reducing the number of EPs – an aim closely aligned
with early presentation in general. How achievable this is depends
on the frequency of symptoms before those that directly lead to the
presentation; in some cases EP might be inevitable, perhaps where
no prior symptoms are felt before a critical event. Overall, the
progression of symptoms experienced leading up to a diagnosis of
cancer is not well understood. In some cases, EP can be the most
clinically appropriate diagnostic route, such as for some acute
haematological cancers. The frequency of EP in lung cancer can be
reduced through public awareness campaigns (Calister, 2012),
potentially reducing the associated mortality. It has been shown
that emergency admissions with rapid mortality are more likely in
those not living with a partner (Blaney and Gavin, 2011) and the
likelihood of EP has been associated with several characteristics of
the patient’s general practice (Bottle et al, 2012). This suggests that
interventions by primary and social care may be effective in
reducing the number of EPs. In primary care, these interventions
might be, for example, significant event audits targeting EPs and
subsequent review of referral practice, perhaps similar to recent
recommendations for the management of existing cases of cancer
to prevent emergency admissions (Royal College of Physicians and
Royal College of Radiologists, 2012).
Mortality could also be reduced by seeking to reduce the impact
of EP, the extent to which this can be achieved depends on the
balance between the share of the excess mortality that is due to the
nature of the tumour and the extent because of care delivered in
emergency settings. The latter could be affected by detailed
examination of causes of death in these cases and subsequent
change of practice in secondary care.
In summary, EP is a strongly predictive leading indicator of
short-term mortality following cancer diagnosis. Although EPs are
more frequent in older persons with advanced cancers and
extensive co-morbidities, these factors do not fully explain the
impact of EP on excess mortality. In particular, EP remains highly
predictive of very short (o1 month) mortality. Further work to
test hypotheses for this association could potentially lead to
significant reductions in mortality immediately following diag-
nosis, in which England fares poorly in international comparisons.
This might take the form of linkage to primary care data to
investigate patient’s interaction with a GP before an EP. The
extension of the Routes to Diagnosis algorithm to international
data sets may also illuminate causal factors that lead to EP.
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